LCK inhibitor (NTRC)

N/A

Report date: 2025/01/26 19:10:07
NME

Base Information

Drug NameLCK inhibitor (NTRC)
Drug Alias NameNTRC-0625-0
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase LCK inhibitors
TargetsTyrosine-protein kinase LCK
Therapy Area/IndicationsInflammationPsoriasisCholangiocarcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCrossfire Oncology BV
China Registration ClassN/A

Develop Information

Active CompaniesCrossfire Oncology BV
Inactive CompaniesN/A
Active IndicationsInflammationPsoriasisCholangiocarcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A